Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGPhase 4INTERVENTIONAL

Multimodal Brain Imaging of the Neural Effects of Methylphenidate in Patients With ADHD

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The investigators' goal is to develop neuroimaging biomarkers to predict response to treatment with methylphenidate, which then can be used in the development of novel pharmacological treatments for attention-deficit/hyperactivity disorder (ADHD). The overall objective of this study is to measure the changes in task-related neural activity related to symptoms of ADHD (measured by functional MRI) and brain glutamate levels (measured by magnetic resonance spectroscopy, MRS) after treatment with methylphenidate (MPH). This will be a double-blind crossover of methylphenidate and placebo in adults with ADHD. Participants will complete neuropsychological testing along with fMRI and MRS scans after a single dose of each treatment.

Who May Be Eligible (Plain English)

Who May Qualify: - right handed Who Should NOT Join This Trial: - pregnant or breast feeding - past or current neurological disorder - non-ADHD cause of cognitive impairment - uncontrolled medical disorder - head trauma with loss of consciousness in the last year or any evidence of functional impairment due to and persisting after head trauma - having an adverse reaction to methylphenidate, or other stimulant medication - having a contraindication to MRI - current smoking Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * right handed Exclusion Criteria: * pregnant or breast feeding * past or current neurological disorder * non-ADHD cause of cognitive impairment * uncontrolled medical disorder * head trauma with loss of consciousness in the last year or any evidence of functional impairment due to and persisting after head trauma * having an adverse reaction to methylphenidate, or other stimulant medication * having a contraindication to MRI * current smoking

Treatments Being Tested

DRUG

Methylphenidate

single dose of 10 mg or 15 mg

DRUG

Placebo

Matching placebo

Locations (1)

Johns Hopkins School of Medicine
Baltimore, Maryland, United States